KEGG   DRUG: OcrelizumabHelp
Entry
D05218                      Drug                                   

Name
Ocrelizumab (USAN);
Ocrelizumab (genetical recombination) (JAN);
Ocrevus (TN)
Product
Formula
C6494H9978N1718O2014S46
Exact mass
145725.8326
Mol weight
145816.0033
Remark
ATC code: L04AA36
Product: D05218<US>
Efficacy
Antirheumatic, Anti-CD20 antibody
  Disease
Multiple sclerosis [DS:H01490]
Comment
Monoclonal antibody
Treatment of rheumatoid arthritis
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA36 Ocrelizumab
      D05218  Ocrelizumab (USAN) <US>
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD20
     D05218  Ocrelizumab (USAN) <US>
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D05218
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05218
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05218
BRITE hierarchy
Other DBs
CAS: 637334-45-3
PubChem: 47206937
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system